Leveraging Relevant Biological Factors in the Treatment of Early HER2-Positive Breast Cancer: Closing the Quality Chasm
Sara Hurvitz, MD
Associate Professor of Medicine
David Geffen School of Medicine, UCLA
Director, Breast Cancer Clinical Research Program
Co- Director, Santa Monica – UCLA Outpatient Oncology Practice
Santa Monica, CA
Heather L. McArthur, MD
Medical Director, Breast Oncology
Cedars-Sinai Medical Center
Los Angeles, CA
This online activity is focused on the care of patients with early HER2-positive breast cancer.
This CME initiative is designed to meet the educational needs of medical oncologists, gynecologic oncologists, gynecologic surgeons, oncology nurses, and other healthcare providers involved in the treatment of patients with early breast cancer.
After completing the CME activity, learners should be better able to:
- Describe the biological markers that characterize the pathologic assessment of HER2-positive breast cancer
- Explain currently available adjuvant treatment regimens for patients with HER2-positive breast cancer
- Review the emerging clinical trial data for dual anti-HER2 strategies with chemotherapy in the adjuvant setting
- Discuss how quality measures may drive practice change to optimize care for patients with HER2-positive advanced breast cancer
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 2.5 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with breast cancer.
Credits: 2.5 ANCC Contact Hours
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.5 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dr. Hurvitz receives funding (paid to UCLA) for contracted research from Amgen, Bayer, BI Pharma, Genentech, GSK, Lilly, Novartis, Pfizer, Roche, PUMA, Merrimack, Medivation, Dignitana, DBI Pharma, Bomarin, Cascadian, and Seattle Genetics. She has traveled for Lilly, Novartis, OBI Pharma, and Bayer.
Dr. McArthur is a consultant for Merck, Spectrum, Synddax, OBI, Calithera, Roche, Lilly, Peregrine, Taplmmune, Amgen, Puma, Immunomedics, and Pfizer. She has also conducted research for Bristol-Myers Squibb, MedImmune, ZioPharm, Lilly, and Merck.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Flavia Piazza, PhD, VP Medical and Scientific Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Submit the evaluation form to Med Learning Group.
You will receive your certification via email within 30 days.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
RELEASE DATE: August 6, 2018
EXPIRATION DATE: August 6, 2019
This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.
Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.